COVID-19 MedDRA version: 23.0 Level: PT Classification code 10051905 Term: Coronavirus infection System Organ Class: 10021881 - Infections and infestations
Conditions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participant must be = 18 years of age at the time of signing the informed consent. 2. Candidate for benefit from passive immunization with antibodies, defined as: (a) Increased risk for inadequate response to active immunization (predicted poor responders to vaccines), defined as; o Elderly, ie, = 60 years old o Obese, ie, BMI = 30 o Congestive heart failure o Chronic obstructive pulmonary disease o Chronic kidney disease, ie, GFR < 30 mL/min/1.73 m2 o Chronic liver disease o Immunocompromised state from solid organ transplant, blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, or use of other immunosuppressive medicines. o Intolerant of vaccine. Defined as previous history of severe adverse event or serious adverse event after receiving any approved vaccine. (b) Increased risk for SARS-CoV-2 infection, defined as those whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19, based on available risk assessment at time of enrollment. Examples include: o Health care workers, including staff of long-term care facilities (including skilled nursing facilities, assisted living facilities, and independent living facilities for senior adults) o Workers in industrial settings shown to have been at high risk for SARS-COV-2 transmission, including but not limited to meatpacking plants o Military personnel residing or working in high density settings including but not limited to barracks, ships, or close-quarters working environments o Students living in dormitory settings o Others living in settings of similar close or high-density proximity 3. Medically stable defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 1 month prior to enrollment, with no acute change in condition at the time of study enrollment as judged by the investigator. 4. Negative result from point of care SARS-CoV-2 serology resting at screening. 5. Contraceptive use by men or women: (a) Male Participants: Contraception for male participants is not required, however, to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue through 365 days following administration of the IMP. (b) Female Participants: -Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply: o Women < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range. o Women = 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment. - Female participants of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Women of childbearing potential who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control, as defined in the p
Exclusion criteria
Exclusion criteria: 1 Significant infection or other acute illness, including fever > 100°F (> 37.8°C) on the day prior to or day of randomization. 2. History of laboratory-confirmed SARS-CoV-2 infection or any positive SARS-CoV-2 result based on available data at screening. 3. History of infection with severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS). 4. Known history of allergy or reaction to any component of the study drug formulation. 5. Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mAb. 6. Any prior receipt of investigational or licensed vaccine or other mAb/biologic indicated for the prevention of SARS-CoV-2 or COVID-19 or expected receipt during the period of study follow-up. 7. Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 8. Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. Receipt of blood products or immunoglobulins, including mAbs, within 6 months, or 5 antibody half-lives if longer than 6 months, prior to screening 10. Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study 11. For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding. 12. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to randomization. 13. Employees of the Sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 14. In nations, states, or other jurisdictions that for legal or ethical reasons bar the enrolment of participants who lack capacity to provide their own informed consent, such subjects are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of COVID-19 through Day 183 To assess the safety and tolerability of a single IM dose of AZD7442 compared to placebo.;Secondary Objective: Key Secondary To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of COVID-19 through Day 366 Other Secondary - To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of SARS-CoV-2 infection - To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of severe or critical symptomatic COVID-19 - To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of COVID-19-related Emergency Department visits - To assess the pharmacokinetics of AZD7442 administered as a single dose of 300 mg IM -To evaluate ADA responses to AZD7442 in serum;Primary end point(s): The primary endpoint is the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring post dose of IMP through Day 183. For safety; AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP.;Timepoint(s) of evaluation of this end point: Day 183 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Key Secondary endpoint; -The key secondary endpoint is the incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness through Day 366. Other Secondary endpoint; - The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 Nucleocapsid antibodies. - The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring post dose. - The incidence of COVID-19-related Emergency Department visits occurring post dose. -Serum AZD7442 concentrations. -PK parameters if data permit. -Incidence of ADA to AZD7442 in serum.;Timepoint(s) of evaluation of this end point: Day 366 | — |
Countries
Belgium, France, Spain, United Kingdom, United States
Contacts
Public ContactInformation Center
AstraZeneca AB
Outcome results
None listed